Topical finasteride aims to deliver the drug to the scalp with less systemic absorption, and studies show it lowers blood DHT less than oral finasteride. It is not FDA-approved and is sold as a compounded product, which the FDA flagged for safety concerns in 2025.
How topical compares with oral
The appeal of topical finasteride is the hope of getting the scalp benefit with fewer body-wide effects. Applied to the scalp, it does reach follicles, and studies suggest it reduces serum (blood) DHT less than oral finasteride while still lowering scalp DHT meaningfully. In trials, topical formulations improved hair counts versus placebo, with effects approaching oral therapy on some measures.
However, "less systemic" does not mean "none." Topical finasteride is still absorbed into the bloodstream, and the same types of side effects associated with oral finasteride — including sexual and mood effects — have been reported with topical use. The reduction in systemic exposure may lower, but does not eliminate, that risk, and the long-term safety and optimal formulation are not as well established as for the oral tablet.
Approval status: not FDA-approved
There is no FDA-approved topical finasteride product. Finasteride is FDA-approved only as an oral tablet (at 1mg for male pattern hair loss and at 5mg for benign prostatic enlargement). Topical versions are dispensed as compounded preparations, meaning they are mixed by pharmacies rather than manufactured and reviewed as a standardized, approved drug. As a result, ingredients, concentration, and quality can vary between sources, and they have not undergone the FDA's review for safety and effectiveness.
The 2025 FDA safety note
In April 2025, the FDA issued an alert about compounded topical finasteride. It described adverse-event reports submitted to its reporting system over roughly the prior five years — including erectile dysfunction, decreased libido, anxiety, depression, suicidal ideation, brain fog, fatigue, insomnia, and testicular pain. The FDA emphasized that these effects mirror those linked to oral finasteride, that most of the reports described symptoms persisting after stopping the product, and that no topical finasteride product is FDA-approved.
The takeaway is not that topical finasteride cannot be used, but that it should be approached with informed caution: it is a compounded, non-approved option whose systemic effects are real if reduced. If you are considering it, discuss the trade-offs with a dermatologist, use a reputable prescriber, and report any side effects. Stop and seek prompt help for any thoughts of self-harm, significant depression, or a severe allergic reaction. This is educational information, not medical advice.
Try the free self-check →FAQ
Is topical finasteride safer than oral?
It generally lowers systemic DHT less than oral finasteride, which may reduce body-wide side effects, but it does not eliminate them — the drug is still absorbed and similar sexual and mood effects have been reported. It is also non-FDA-approved and compounded, so quality varies. Discuss the trade-offs with a clinician.
Is topical finasteride FDA-approved?
No. Finasteride is FDA-approved only as an oral tablet. Topical finasteride is available as a compounded preparation, which is not reviewed by the FDA for safety or effectiveness. In April 2025 the FDA issued a safety alert about adverse events linked to compounded topical finasteride products.
Explore more
⚠️ When to see a doctor — don’t self-treat
- Sudden patchy or circular bald spots
- Redness, scaling, pus, pain or itch (possible scarring alopecia — treat urgently)
- Broken hairs or rapid loss
- Loss with body-wide signs (weight loss, fatigue, cycle changes, acne, extra hair)
- Loss right after a new medication
- Any hair loss in a child